Market Place
Sourcing Support
ADMA Refutes Misleading Allegations By Culper Research
27 Mar 2026 //
GLOBENEWSWIRE
ADMA Biologics Addresses Misleading Short-Seller Report
25 Mar 2026 //
GLOBENEWSWIRE
ADMA Bio Initiates $125M Accelerated Share Repurchase
02 Mar 2026 //
GLOBENEWSWIRE
ADMA Biologics Reports Q4 and FY 2025 Results on Feb. 25, 2026
18 Feb 2026 //
GLOBENEWSWIRE
ADMA Biologics Reveals 2025 Revenue, Updates Business
12 Jan 2026 //
GLOBENEWSWIRE
ADMA Bio Reveals Q3 2025 Financials & Business Update
05 Nov 2025 //
GLOBENEWSWIRE
ADMA Biologics Announces Partial Paydown of Senior Facility
20 Dec 2024 //
GLOBENEWSWIRE
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
14 Aug 2024 //
GLOBENEWSWIRE
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
01 Aug 2024 //
GLOBENEWSWIRE
ADMA Bio Announces $135 Million Non-Dilutive Refinancing of Credit Facilities
18 Dec 2023 //
GLOBENEWSWIRE
ADMA Biologics Announces FDA Approval for ASCENIV & BIVIGAM
13 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Closing of $69 Million Public Offering
09 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Pricing of Public Offering for $60 M of Common Stock
07 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
06 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Proposed Public Offering of Common Stock
06 Dec 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Q2 Financial Results and Provides Business Update
10 Aug 2022 //
GLOBENEWSWIRE
ADMA Biologics to Report Second Quarter 2022 Financial Results
03 Aug 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Addition to the Russell 2000 Index
21 Jun 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
04 May 2022 //
GLOBENEWSWIRE
ADMA Announces Live Poster Presentation and Symposium with ASCENIV at CIS 2022
01 Apr 2022 //
GLOBENEWSWIRE
FDA Approves Extended Shelf Life for ADMA`s ASCENIV & BIVIGAM from 24-36 Months
25 Mar 2022 //
GLOBENEWSWIRE
ADMA Biologics Announces Q4 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
ADMA Biologics to Report Q4 and Full Year 2021 Financial Results on March 24
21 Mar 2022 //
GLOBENEWSWIRE
ADMA Biologics: Prelim Q4 and Full Year 2021 Revenues & 2022 Business Update
19 Jan 2022 //
GLOBENEWSWIRE
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center
18 Jan 2022 //
GLOBENEWSWIRE
ADMA Biologics Provides Update on Global Intellectual Property Portfolio
09 Dec 2021 //
GLOBENEWSWIRE
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman
17 Nov 2021 //
GLOBENEWSWIRE
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening
16 Nov 2021 //
GLOBENEWSWIRE
ADMA Biologics Reports Record Third Quarter 2021 Financial Results &Highlights
10 Nov 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces Closing of $57.5 Million Public Offering
25 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
22 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces Pricing of Public Offering for $50 M Common Stock
21 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces Proposed Public Offering of Common Stock
20 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces a Poster Presentation at the 2021 International Society
19 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces the Presentation of Real-World Experience in (RSV)
04 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics Announces the Presentation of Real-World Experience in (RSV)
04 Oct 2021 //
GLOBENEWSWIRE
ADMA Biologics to Virtually Participate in the Cantor Healthcare Conference
23 Sep 2021 //
GLOBENEWSWIRE
ADMA Biologics Gains FDA Approval for VanRx Aseptic Ops
09 Sep 2021 //
CONTRACT PHARMA
FDA approves ADMA Biologics` VanRx Aseptic Fill-Finish Machine
08 Sep 2021 //
GLOBENEWSWIRE
ADMA Biologics to Participate in the Morgan Stanley 19th Annual Conference
01 Sep 2021 //
BIO SPACE
ADMA Biologics Receives FDA Approval for ADMA BioCenters
16 Aug 2021 //
GLOBENEWSWIRE
ADMA Biologics Reports Q1 2021 Financial Results and Highlights
12 May 2021 //
GLOBENEWSWIRE
FDA Approves ADMA Biologics Increased IVIG Production
29 Apr 2021 //
CONTRACTPHARMA
ADMA Biologics’ Increased IVIG Production Scale Gets FDA Nod; Shares Gain
28 Apr 2021 //
NASDAQ
ADMA Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV
13 Apr 2021 //
NEUROAMERICA
ADMA Biologics Presents Late-Breaking Poster Presentation Clinical Utility
26 Feb 2021 //
PRESS RELEASE
ADMA Biologics Receives Unique Permanent J-Code for ASCENIV™
26 Jan 2021 //
GLOBENEWSWIRE
ADMA Biologics Receives Unique Temporary C-Code and Pass-Through
04 Jan 2021 //
GLOBENEWSWIRE
ADMA Biologics Opens New Plasma Collection Facility
06 Jul 2020 //
CONTRACTPHARMA
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
06 Feb 2020 //
GLOBENEWSWIRE
ADMA Biologics Enters Mfg. and Supply Agreement
08 Jan 2020 //
CONTRACT PHARMA
ADMA Biologics Enters Mfg. and Supply Agreement
07 Jan 2020 //
CONTRACT PHARMA
ADMA Biologics Enters Mfg. and Supply Agreement
07 Jan 2020 //
CONTRACT PHARMA
ADMA Biologics gets FDA Approval for License Transfers for BIVIGAM® and Nabi-HB
08 Jul 2019 //
GLOBE NEWSWIRE
ADMA Biologics returning Bivigam to market after 3-year absence
14 May 2019 //
FIERCE PHARMA
ADMA Biologics Enters Into $72.5 Million Financing with Perceptive Advisors
12 Feb 2019 //
GLOBENEWSWIRE
